5:32 PM
 | 
Dec 19, 2012
 |  BC Extra  |  Company News

NHS to reimburse for Kalydeco in England

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said the NHS will reimburse the company's cystic fibrosis (CF) drug Kalydeco ivacaftor in England, effective Jan. 1, 2013. Vertex will provide the drug under a patient access scheme, but declined to disclose details. The drug's annual list price in the U.K. is L182,625 ($294,651), with about 270 eligible...

Read the full 252 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >